# Stoneridge Inc: financial statements, quarterly

SRI · NYSE · CIK 1043337 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sri.md) · [Financials](/companies/sri/financials.md) · [Filings](/companies/sri/filings.md) · [Insiders](/companies/sri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sri/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [238](/filings/0001043337-24-000121.md) | [230 d](/filings/0001043337-26-000023.md) | [239](/filings/0001043337-25-000092.md) | [237](/filings/0001043337-25-000115.md) | [214](/filings/0001043337-25-000125.md) | [218 d](/filings/0001043337-26-000023.md) | [149](/filings/0001043337-26-000052.md) | [158](/filings/0001043337-26-000074.md) | [210](/filings/0001043337-25-000125.md) | [205 d](/filings/0001043337-26-000023.md) | [161](/filings/0001043337-26-000052.md) | [181](/filings/0001043337-26-000074.md) |
| Cost of revenue | $m | [186](/filings/0001043337-24-000121.md) | [184 d](/filings/0001043337-26-000023.md) | [191](/filings/0001043337-25-000092.md) | [183](/filings/0001043337-25-000115.md) | [169](/filings/0001043337-25-000125.md) | [176 d](/filings/0001043337-26-000023.md) | [114](/filings/0001043337-26-000052.md) | [121](/filings/0001043337-26-000074.md) | [167](/filings/0001043337-25-000125.md) | [172 d](/filings/0001043337-26-000023.md) | [126](/filings/0001043337-26-000052.md) | [145](/filings/0001043337-26-000074.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [17.9](/filings/0001043337-24-000121.md) | [13.6 d](/filings/0001043337-26-000023.md) | [17.6](/filings/0001043337-25-000092.md) | [18.5](/filings/0001043337-25-000115.md) | [17.6](/filings/0001043337-25-000125.md) | [18.5 d](/filings/0001043337-26-000023.md) | [13.7](/filings/0001043337-26-000052.md) | [14.8](/filings/0001043337-26-000074.md) | [14.5](/filings/0001043337-25-000125.md) | [11.5 d](/filings/0001043337-26-000023.md) | [11.4](/filings/0001043337-26-000052.md) | [12.0](/filings/0001043337-26-000074.md) |
| Selling, general and administrative | $m | [28.1](/filings/0001043337-24-000121.md) | [25.9 d](/filings/0001043337-26-000023.md) | [30.4](/filings/0001043337-25-000092.md) | [31.9](/filings/0001043337-25-000115.md) | [26.5](/filings/0001043337-25-000125.md) | [28.6 d](/filings/0001043337-26-000023.md) | [25.9](/filings/0001043337-26-000052.md) | [25.7](/filings/0001043337-26-000074.md) | [31.6](/filings/0001043337-25-000125.md) | [29.5 d](/filings/0001043337-26-000023.md) | [32.5](/filings/0001043337-26-000052.md) | [26.1](/filings/0001043337-26-000074.md) |
| Operating income | $m | [6.5](/filings/0001043337-24-000121.md) | [6.0 d](/filings/0001043337-26-000023.md) | [0.3](/filings/0001043337-25-000092.md) | [3.4](/filings/0001043337-25-000115.md) | [0.3](/filings/0001043337-25-000125.md) | [(4.4) d](/filings/0001043337-26-000023.md) | [(4.3)](/filings/0001043337-26-000052.md) | [(4.2)](/filings/0001043337-26-000074.md) | [(3.3)](/filings/0001043337-25-000125.md) | [(29.5) d](/filings/0001043337-26-000023.md) | [(9.0)](/filings/0001043337-26-000052.md) | [(1.2)](/filings/0001043337-26-000074.md) |
| Interest expense | $m | [3.3](/filings/0001043337-23-000056.md) | [(22.2) d](/filings/0001043337-24-000007.md) | [3.6](/filings/0001043337-24-000089.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.3](/filings/0001043337-24-000121.md) | [0.2 d](/filings/0001043337-26-000023.md) | [0.5](/filings/0001043337-25-000092.md) | [(0.9)](/filings/0001043337-25-000115.md) | [3.4](/filings/0001043337-25-000125.md) | [(0.1) d](/filings/0001043337-26-000023.md) | [1.6](/filings/0001043337-26-000052.md) | [1.5](/filings/0001043337-26-000074.md) | [(0.3)](/filings/0001043337-25-000125.md) | [45.9 d](/filings/0001043337-26-000023.md) | [1.4](/filings/0001043337-26-000052.md) | [2.6](/filings/0001043337-26-000074.md) |
| Net income | $m | [2.2](/filings/0001043337-24-000121.md) | [3.0 d](/filings/0001043337-26-000023.md) | [(6.1)](/filings/0001043337-25-000125.md) | [2.8](/filings/0001043337-25-000125.md) | [(7.1)](/filings/0001043337-25-000125.md) | [(6.1) d](/filings/0001043337-26-000023.md) | [(7.2)](/filings/0001043337-26-000074.md) | [(9.4)](/filings/0001043337-26-000074.md) | [(9.4)](/filings/0001043337-25-000125.md) | [(76.9) d](/filings/0001043337-26-000023.md) | [(27.9)](/filings/0001043337-26-000074.md) | [(5.3)](/filings/0001043337-26-000074.md) |
| Diluted EPS | $ per share | [0.08](/filings/0001043337-24-000121.md) | not reported | [(0.22)](/filings/0001043337-25-000092.md) | [0.10](/filings/0001043337-25-000115.md) | [(0.26)](/filings/0001043337-25-000125.md) | not reported | [(0.26)](/filings/0001043337-26-000052.md) | [(0.34)](/filings/0001043337-26-000074.md) | [(0.34)](/filings/0001043337-25-000125.md) | not reported | [(1.00)](/filings/0001043337-26-000052.md) | [(0.19)](/filings/0001043337-26-000074.md) |
| Basic EPS | $ per share | [0.08](/filings/0001043337-24-000121.md) | not reported | [(0.22)](/filings/0001043337-25-000092.md) | [0.10](/filings/0001043337-25-000115.md) | [(0.26)](/filings/0001043337-25-000125.md) | not reported | [(0.26)](/filings/0001043337-26-000052.md) | [(0.34)](/filings/0001043337-26-000074.md) | [(0.34)](/filings/0001043337-25-000125.md) | not reported | [(1.00)](/filings/0001043337-26-000052.md) | [(0.19)](/filings/0001043337-26-000074.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.8](/filings/0001043337-23-000056.md) | [40.8](/filings/0001043337-25-000012.md) | [48.4](/filings/0001043337-24-000089.md) | [42.1](/filings/0001043337-24-000106.md) | [54.1](/filings/0001043337-24-000121.md) | [71.8](/filings/0001043337-26-000023.md) | [79.1](/filings/0001043337-25-000092.md) | [49.8](/filings/0001043337-25-000115.md) | [54.0](/filings/0001043337-25-000125.md) | [53.1](/filings/0001043337-26-000074.md) | [70.5](/filings/0001043337-26-000052.md) | [71.5](/filings/0001043337-26-000074.md) |
| Current assets | $m | [436](/filings/0001043337-23-000056.md) | [429](/filings/0001043337-25-000012.md) | [431](/filings/0001043337-24-000089.md) | [422](/filings/0001043337-24-000106.md) | [414](/filings/0001043337-24-000121.md) | [388](/filings/0001043337-26-000023.md) | [418](/filings/0001043337-25-000092.md) | [393](/filings/0001043337-25-000115.md) | [384](/filings/0001043337-25-000125.md) | [362](/filings/0001043337-26-000074.md) | [348](/filings/0001043337-26-000052.md) | [344](/filings/0001043337-26-000074.md) |
| Total assets | $m | [679](/filings/0001043337-23-000056.md) | [680](/filings/0001043337-25-000012.md) | [675](/filings/0001043337-24-000089.md) | [667](/filings/0001043337-24-000106.md) | [663](/filings/0001043337-24-000121.md) | [622](/filings/0001043337-26-000023.md) | [657](/filings/0001043337-25-000092.md) | [639](/filings/0001043337-25-000115.md) | [632](/filings/0001043337-25-000125.md) | [551](/filings/0001043337-26-000074.md) | [512](/filings/0001043337-26-000052.md) | [507](/filings/0001043337-26-000074.md) |
| Current liabilities | $m | [382](/filings/0001043337-23-000056.md) | [178](/filings/0001043337-25-000012.md) | [180](/filings/0001043337-24-000089.md) | [186](/filings/0001043337-24-000106.md) | [170](/filings/0001043337-24-000121.md) | [150](/filings/0001043337-26-000023.md) | [175](/filings/0001043337-25-000092.md) | [184](/filings/0001043337-25-000115.md) | [180](/filings/0001043337-25-000125.md) | [157](/filings/0001043337-26-000074.md) | [173](/filings/0001043337-26-000052.md) | [182](/filings/0001043337-26-000074.md) |
| Long-term debt | $m | [0.0](/filings/0001043337-23-000056.md) | [0.0](/filings/0001043337-25-000012.md) | [0.0](/filings/0001043337-24-000089.md) | [0.0](/filings/0001043337-24-000106.md) | [0.0](/filings/0001043337-24-000121.md) | [0.0](/filings/0001043337-25-000125.md) | not reported | not reported | [0.0](/filings/0001043337-25-000125.md) | [181](/filings/0001043337-26-000023.md) | not reported | not reported |
| Current portion of debt | $m | [186](/filings/0001043337-23-000056.md) | [2.1](/filings/0001043337-25-000012.md) | [2.1](/filings/0001043337-24-000089.md) | [2.1](/filings/0001043337-24-000106.md) | [0.0](/filings/0001043337-24-000121.md) | [0.0](/filings/0001043337-25-000125.md) | not reported | not reported | [0.9](/filings/0001043337-25-000125.md) | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [273](/filings/0001043337-24-000121.md) | [288](/filings/0001043337-26-000023.md) | [277](/filings/0001043337-25-000125.md) | [270](/filings/0001043337-25-000125.md) | [271](/filings/0001043337-25-000125.md) | [245](/filings/0001043337-26-000074.md) | [253](/filings/0001043337-26-000074.md) | [261](/filings/0001043337-26-000074.md) | [251](/filings/0001043337-25-000125.md) | [180](/filings/0001043337-26-000074.md) | [156](/filings/0001043337-26-000074.md) | [149](/filings/0001043337-26-000074.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.0) d](/filings/0001043337-24-000121.md) | [10.6 d](/filings/0001043337-26-000023.md) | [9.1](/filings/0001043337-25-000092.md) | [8.7 d](/filings/0001043337-25-000115.md) | [10.8 d](/filings/0001043337-25-000125.md) | [19.2 d](/filings/0001043337-26-000023.md) | [10.9](/filings/0001043337-25-000092.md) | [10.7 d](/filings/0001043337-25-000115.md) | [3.6 d](/filings/0001043337-25-000125.md) | [8.8 d](/filings/0001043337-26-000023.md) | [(11.5)](/filings/0001043337-26-000052.md) | [12.3 d](/filings/0001043337-26-000074.md) |
| Capital expenditure | $m | [9.0](/filings/0001043337-23-000056.md) | [15.3 d](/filings/0001043337-26-000023.md) | [5.8](/filings/0001043337-25-000092.md) | [7.1 d](/filings/0001043337-25-000115.md) | [6.1 d](/filings/0001043337-25-000125.md) | [5.3 d](/filings/0001043337-26-000023.md) | [6.1](/filings/0001043337-26-000052.md) | [3.3 d](/filings/0001043337-26-000074.md) | [6.3 d](/filings/0001043337-25-000125.md) | [6.2 d](/filings/0001043337-26-000023.md) | [0.8](/filings/0001043337-26-000052.md) | [4.6 d](/filings/0001043337-26-000074.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.5](/filings/0001043337-23-000056.md) | [27.3](/filings/0001043337-24-000089.md) | [27.5](/filings/0001043337-24-000106.md) | [27.7](/filings/0001043337-24-000121.md) | [27.5](/filings/0001043337-25-000092.md) | [27.9](/filings/0001043337-25-000115.md) | [27.6](/filings/0001043337-25-000125.md) | [27.7](/filings/0001043337-26-000052.md) | [27.8](/filings/0001043337-26-000074.md) | [27.9](/filings/0001043337-25-000125.md) | [27.9](/filings/0001043337-26-000052.md) | [28.2](/filings/0001043337-26-000074.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,522,874 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001043337-26-000074.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.